A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Recruiting

Phase 1

CBI-1214A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Sponsor:

Cartography Biosciences

Code:

NCT07321106

Conditions

Colorectal Cancer

Colorectal Cancer (CRC)

Colorectal (Colon or Rectal) Cancer

CRC

Metastatic Colon Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CBI-1214

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by Cartography Biosciences on 2026-01-06.